Sigma rejects revised offer from Aspen
Monday, 12 July, 2010
Melbourne biotech Sigma Pharmaceuticals has assured shareholders that it is trying to negotiate a better deal than the revised $0.55 a share offered for the company by South African generics producer Aspen Pharmacare Holdings.
The original offer was for $0.60 but was reduced in the light of poor financial data from Sigma last month.
In a letter issued to the ASX today company secretary Sue Morgan Dethick said that Sigma was focussed on having a number of conditions proposed by Aspen removed, but urged this did not mean it was satisfied with the revised price, which values the company at $700 million. Aspen has however indicated that it is running out patience.
One of Australia’s oldest pharmaceutical companies Sigma owns a number of household retail brands including Amcal, Guardian and the Amcal Max brand. However, it recently fallen on hard times, posting a $389 million loss for the year ending January 31, 2010.
Last month it revealed that its generics business was $6.4 million under budget, leading some analysts to downgrade the company from neutral to underperform.
Sigma’s shares closed today at $0.45.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
